Cargando…

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database

INTRODUCTION: Oral glucocorticoids (GC) have been the mainstay of treatment for giant cell arteritis (GCA). We estimated the risk and dose–effect relationship of potential GC-related adverse events (AEs) in patients with GCA. METHODS: This retrospective, observational cohort study utilized data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Best, Jennie H., Kong, Amanda M., Unizony, Sebastian, Tran, Oth, Michalska, Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858477/ https://www.ncbi.nlm.nih.gov/pubmed/31656021 http://dx.doi.org/10.1007/s40744-019-00180-9

Ejemplares similares

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
por: Best, Jennie H, et al.
Publicado: (2019)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK
por: Gale, Sara, et al.
Publicado: (2018)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations
por: Unizony, Sebastian, et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Estimating the Cost of Illness of Giant Cell Arteritis in the United States
por: Babigumira, Joseph B., et al.
Publicado: (2017)

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis
por: Jakobsson, Karin, et al.
Publicado: (2016)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis
por: Karabayas, Maira, et al.
Publicado: (2020)

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice
por: Craig, Gary, et al.
Publicado: (2021)

An Updated Review of Cardiovascular Events in Giant Cell Arteritis
por: de Boysson, Hubert, et al.
Publicado: (2022)

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019)

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering
por: Venerito, Vincenzo, et al.
Publicado: (2022)

The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
por: Patel, Naomi J., et al.
Publicado: (2021)

Glucocorticoid Effects on Tissue Residing Immune Cells in Giant Cell Arteritis: Importance of GM-CSF
por: Wagner, Annette D., et al.
Publicado: (2021)

Giant Cell Arteritis
por: Coulier, Bruno, et al.
Publicado: (2018)

Giant Cell Arteritis versus Takayasu Arteritis: An Update
por: Stamatis, Pavlos
Publicado: (2020)

A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis
por: Hoon, Elizabeth, et al.
Publicado: (2019)

Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis
por: Castan, Paul, et al.
Publicado: (2022)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
por: Hellmich, B., et al.
Publicado: (2020)

Specific microbiome profile in Takayasu’s arteritis and giant cell arteritis
por: Desbois, Anne Claire, et al.
Publicado: (2021)

Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study
por: Jamilloux, Yvan, et al.
Publicado: (2013)

From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide
por: Kuret, Tadeja, et al.
Publicado: (2022)

Bone mineral density in patients diagnosed with giant cell arteritis taking glucocorticoids: a case–control study
por: Geressu, Adam, et al.
Publicado: (2023)

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2020)

Correction: Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study
por: Jamilloux, Yvan, et al.
Publicado: (2013)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Baseline Glucocorticoid‐Related Toxicity Scores in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
por: Patel, Naomi J., et al.
Publicado: (2023)

Doppler ultrasound and giant cell arteritis
por: Suelves, Ana Marina, et al.
Publicado: (2010)

An Unusual Presentation of Giant Cell Arteritis
por: Prabhavalkar, Siddhesh, et al.
Publicado: (2012)

Biologic Therapies for Giant Cell Arteritis
por: Harrington, Robert, et al.
Publicado: (2021)

Giant Cell Arteritis and Cardiac Comorbidity
por: Arias, Magela, et al.
Publicado: (2021)

Advances in the Treatment of Giant Cell Arteritis
por: Castañeda, Santos, et al.
Publicado: (2022)

Treatment of Giant Cell Arteritis (GCA)
por: Régent, Alexis, et al.
Publicado: (2022)

An Unusual Case of Giant Cell Arteritis
por: Goyal, Nitasha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hh7j3bg4s854no9952h3c1s1ha